(57 days)
No
The summary describes a standard MRI system with noise reduction technology and mentions modifications to a previously cleared device. There is no mention of AI, ML, or any related concepts in the intended use, device description, or performance studies.
No
The device is described as a diagnostic imaging modality that produces images useful in diagnosis, not for treating conditions.
Yes
The "Intended Use / Indications for Use" section explicitly states that the system is a "diagnostic imaging modality" and that "When interpreted by a trained physician, these images yield information that can be useful in diagnosis."
No
The device description clearly states it is a 1.5 Tesla Magnetic Resonance Imaging (MRI) System, which is a hardware device. The summary also mentions hardware components like the magnet, gradient coil, and whole body coil.
Based on the provided text, the Vantage Titan system is not an IVD (In Vitro Diagnostic) device.
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens (like blood, urine, or tissue) taken from the human body to provide information for diagnosis, monitoring, or screening.
- Vantage Titan Function: The Vantage Titan is an MRI system that produces images of the internal structures of the head and body. It works by using magnetic fields and radio waves to create these images, not by analyzing biological specimens.
- Intended Use: The intended use clearly states it's a "diagnostic imaging modality" that produces images of "anatomic structures." This aligns with in vivo imaging, not in vitro analysis.
Therefore, the Vantage Titan is a medical imaging device, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
Vantage Titan systems are indicated for use as a diagnostic imaging modality that produces cross-sectional transaxial, coronal, sagittal, and oblique images that display anatomic structures of the head or body. Additionally, this system is capable of non-contrast enhanced imaging, such as MRA.
MRI (magnetic resonance imaging) images correspond to the spatial distribution of protons (hydrogen nuclei) that exhibit nuclear magnetic resonance (NMR). The NMR properties of body tissues and fluids are:
- · Proton density (PD) (also called hydrogen density)
- · Spin-lattice relaxation time (T1)
- · Spin-spin relaxation time (T2)
- · Flow dynamics
- · Chemical Shift
Contrast agent use is restricted to the approved drug indications. When interpreted by a trained physician, these images yield information that can be useful in diagnosis.
Product codes
LNH
Device Description
The Vantage Titan (Model MRT-1510) is a 1.5 Tesla Magnetic Resonance Imaging (MRI) System. The Vantage Titan uses 1.4m short and 4.1 tons light weight magnet. It includes the Toshiba Pianissimo™ technology (scan noise reduction technology). The design of the gradient coil and the whole body coil of the Vantage Titan provides the maximum field of view of 55 x 55 x 50 cm. The Vantage Titan MRI System is comparable to the current 1.5T EXCELART Vantage Titan MRI System (K120638), cleared Jun 1, 2012 with the following modifications.
SUMMARY OF HARDWARE CHANGES
- a. Main magnet has been changed from OR76 to TN150 (MRT-1510/1A) or OR200 (MRT-1510/2A).
- b. System power requirements has been changed from 200V and 400V to 380/400/415/480 V.
SUMMARY OF SOFTWARE CHANGES
- a. New Operating System (Windows 7)
- b. WFS (Water Fat Separation) to provide water dominant images and fat dominant images.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Magnetic Resonance Imaging (MRI)
Anatomical Site
head or body
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Testing was performed using archived clinical images, simulation testing and bench (phantom) testing. This testing demonstrated that the implementation of the modifications retained the safety and effectiveness of the cleared device.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.1000 Magnetic resonance diagnostic device.
(a)
Identification. A magnetic resonance diagnostic device is intended for general diagnostic use to present images which reflect the spatial distribution and/or magnetic resonance spectra which reflect frequency and distribution of nuclei exhibiting nuclear magnetic resonance. Other physical parameters derived from the images and/or spectra may also be produced. The device includes hydrogen-1 (proton) imaging, sodium-23 imaging, hydrogen-1 spectroscopy, phosphorus-31 spectroscopy, and chemical shift imaging (preserving simultaneous frequency and spatial information).(b)
Classification. Class II (special controls). A magnetic resonance imaging disposable kit intended for use with a magnetic resonance diagnostic device only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.
0
Image /page/0/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is an emblem featuring a stylized representation of three human profiles facing to the right, with flowing lines suggesting movement or connection.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
September 10, 2015
Toshiba Medical Systems Corporation % Mr. Paul Biggins Director Regulatory Affairs/ U.S. Agent Toshiba America Medical Systems, Inc. 2441 Michelle Drive TUSTIN. CA 92780
Re: K150427
Trade/Device Name: Vantage Titan 1.5T, MRT-1510 Regulation Number: 21 CFR 892.1000 Regulation Name: Magnetic Resonance Diagnostic Device Regulatory Class: II Product Code: LNH Dated: February 18, 2015 Received: February 19, 2015
Dear Mr. Biggins:
This letter corrects our substantially equivalent letter of April 17, 2015.
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
1
forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act): 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Robert Oolo
Robert Ochs, Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K150427
Device Name
Vantage Titan 1.5T, MRT-1510
Indications for Use (Describe)
Vantage Titan systems are indicated for use as a diagnostic imaging modality that produces cross-sectional transaxial, coronal, sagittal, and oblique images that display anatomic structures of the head or body. Additionally, this system is capable of non-contrast enhanced imaging, such as MRA.
MRI (magnetic resonance imaging) images correspond to the spatial distribution of protons (hydrogen nuclei) that exhibit nuclear magnetic resonance (NMR). The NMR properties of body tissues and fluids are:
- · Proton density (PD) (also called hydrogen density)
- · Spin-lattice relaxation time (T1)
- · Spin-spin relaxation time (T2)
- · Flow dynamics
- · Chemical Shift
Contrast agent use is restricted to the approved drug indications. When interpreted by a trained physician, these images yield information that can be useful in diagnosis.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) SUMMARY OF SAFETY AND EFFECTIVENESS
1. CLASSIFICATION and DEVICE NAME:
| Classification Name: | Magnetic Resonance Diagnostic Device |
|---|---|
| Regulation Number: | 90-LNH (Per 21 CFR 892.1000) |
| Trade Proprietary Name: | Vantage Titan 1.5T |
| Model Number: | MRT-1510 |
2. ESTABLISHMENT REGISTRATION: 9614698
3. Toshiba Medical Systems Corporation (TMSC) 1385 Shimoishigami Otawara-shi, Tochigi 324-8550, Japan
4. Contact Person, U.S AGENT and ADDRESS:
U.S. Agent Name:
Paul Biggins Director, Regulatory Affairs Toshiba America Medical Systems, Inc. (TAMS) 2441 Michelle Drive Tustin, Ca. 92780 (714) 699-7808
5. MANUFACTURING SITE:
Toshiba Medical Systems Corporation (TMSC) 1385 Shimoishigami Otawara-shi, Tochigi 324-8550, Japan
6. DATE OF SUBMISSION:
February 18th, 2015
7. DEVICE DESCRIPTION:
The Vantage Titan (Model MRT-1510) is a 1.5 Tesla Magnetic Resonance Imaging (MRI) System. The Vantage Titan uses 1.4m short and 4.1 tons light weight magnet. It includes the Toshiba Pianissimo™ technology (scan noise reduction technology). The design of the gradient coil and the whole body coil of the Vantage Titan provides the maximum field of view of 55 x 55 x 50 cm. The Vantage Titan MRI System is comparable to the current 1.5T EXCELART Vantage Titan MRI System (K120638), cleared Jun 1, 2012 with the following modifications.
Page 1 of 4
4
7.1 SUMMARY OF HARDWARE CHANGES
- a. Main magnet has been changed from OR76 to TN150 (MRT-1510/1A) or OR200 (MRT-1510/2A).
- b. System power requirements has been changed from 200V and 400V to 380/400/415/480 V.
7.2 SUMMARY OF SOFTWARE CHANGES
- a. New Operating System (Windows 7)
- b. WFS (Water Fat Separation) to provide water dominant images and fat dominant images.
8. SAFETY PARAMETERS
Table 1: Primary Predicate Device
| Item | Vantage Titan
(subject device) | Vantage Titan K120638
(Predicate Device) | Notes |
|------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|---------|
| Static field strength | 1.5T | 1.5T | Same |
| Operational Modes
i. Safety parameter display | 1st Operating Mode
SAR dB/dt | 1st Operating Mode
SAR dB/dt | Same |
| ii. Operating mode
access requirements | Allows screen
access to 1st level
operating mode | Allows screen
access to 1st level
operating mode | Same |
| Maximum SAR | 4W/kg for whole
body (1st operating
mode specified in
IEC 60601-2-
33(2010)) | 4W/kg for whole
body (1st operating
mode specified in
IEC 60601-2-
33(2002)) | Change* |
| Maximum dB/dt | 1st operating mode
specified in
IEC 60601-2-33
(2010) | 1st operating mode
specified in
IEC 60601-2-33
(2002) | Change* |
| Potential emergency
condition and means
provided for
shutdown | Shut down by
Emergency Ramp
Down Unit for
collision hazard for
ferromagnetic
objects | Shut down by
Emergency Ramp
Down Unit for
collision hazard for
ferromagnetic
objects | Same |
*Note: The difference between predicate and subject device is due to the conformance of the subject device to IEC 60601-2-33 (2010)
5
9. IMAGING PERFORMACE PARAMETERS
No change from the previous predicate submission (K120638).
10. INTENDED USE
Vantage Titan systems are indicated for use as a diagnostic imaging modality that produces cross-sectional transaxial, coronal, sagittal, and oblique images that display anatomic structures of the head or body. Additionally, this system is capable of noncontrast enhanced imaging, such as MRA.
MRI (magnetic resonance imaging) images correspond to the spatial distribution of protons (hydrogen nuclei) that exhibit nuclear magnetic resonance (NMR). The NMR properties of body tissues and fluids are:
- . Proton density (PD) (also called hydrogen density)
- . Spin-lattice relaxation time (T1)
- Spin-spin relaxation time (T2)
- . Flow dynamics
- . Chemical Shift
Contrast agent use is restricted to the approved drug indications. When interpreted by a trained physician, these images yield information that can be useful in diagnosis.
No changes to the previously cleared indication (K120638).
11. SUMMARY OF DESIGN CONTROL ACTIVITIES
PS Risk List for system and software are included in this submission. The test methods used are the same as those submitted in the previously cleared submissions (K120638). A declaration of conformity with design controls is included in this submission.
12. TRUTHFUL AND ACCURACY CERTIFICATION
A certification of the truthfulness and accuracy of the Vantage Titan 1.5T described in this submission is provided in this submission.
13. SUBSTANTIAL EQUIVALENCE
This device is substantially equivalent to the 1.5T EXCELART Vantage Titan MRI System (K120638), marketed by Toshiba America Medical Systems. Vantage Titan 1.5T, V3.1. MRT 1510 includes additional software features. The additional software features have the same intended use as the secondary predicate device, listed below in table one. Testing was performed using archived clinical images, simulation testing and bench (phantom) testing. This testing demonstrated that the implementation of the modifications retained the safety and effectiveness of the cleared device.
6
Toshiba Medical Systems Corporation believes that the Vantage Titan 1.5T (model MRT-1510) Magnetic Resonance Imaging (MRI) System is substantially equivalent to the previously cleared predicate devices referenced in this submission.
| 510 (k) Number | Clearance Date | Device Name | Manufacturer |
|---|---|---|---|
| K120638 | |||
| Primary Predicate | |||
| (System) | 06/01/2012 | 1.5T EXCELART | |
| Vantage Titan | Toshiba America | ||
| Medical Systems | |||
| K141472 | |||
| Secondary Predicate | |||
| (Magnet) | 09/19/2014 | Vantage Elan 1.5 T | Toshiba America |
| Medical Systems | |||
| K143008 | |||
| Secondary Predicate | |||
| (Software Features) | RTA - 10/31/2014 | Vantage Titan 3T, | |
| V2.50 Software | Toshiba America | ||
| Medical Systems |
Table 2: Primary and Secondary Predicate Device
Testing was done in accordance with applicable recognized consensus standards as listed below.
List of Applicable Standards
- IEC60601-1:2005
- IEC60601-1-2:2007
- · IEC60601-1-8:2003,Amd.1:2006
- · IEC60601-2-33:2010
- · IEC60825-1: 2007
- · IEC62304:2006
- IEC62366:2007
- NEMA MS-1:2008
- NEMA MS-2:2008
- · NEMA MS-3:2008
- · NEMA MS-4:2010
- · NEMA MS-5:2010
Based upon bench testing and phantom image studies Toshiba Medical Systems Corporation believes this system has characteristics that are compatible with currently marketed devices and has proven substantively that this system performed as specified and did not raise new issues of safety and effectiveness. Furthermore, this system does not offer new intended or indicated use when compared to the predicate. Based upon this information, Toshiba believes that it has established substantial equivalence to this device and the predicate.
April 6th, 2015